Frontiers
US$ 23.56
glp-1 agonist benefits Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Part 3 of a 3-Part
Description
Daly T, Okholm S, Imbimbo BP
Results from a study examining the safety of using liraglutide in patients with moderate to severe renal impairment demonstrated no deleterious effects on serum creatinine (SCr) or increased incidence or severity of adverse events
Gut hormones used in newer medications have different mechanisms of action, Davies said, and combination therapy can be used to potentially enhance the efficacy of pharmacotherapy
[Google Scholar] 13.Pi-Sunyer X., Astrup A., Fujioka K., Greenway F., Halpern A., Krempf M., Lau D.C., le Roux C.W., Violante Ortiz R., Jensen C.B., et al
